Treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO); treatment of noninfective uveitis affecting the posterior segment of the eye; treatment of diabetic macular edema(UTD).

Decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response.

Absorption:
Ocular implant: Systemic levels negligible in majority of patients (?50 pg/mL) ?90 days following implant, highest systemic concentration observed: 102 pg/mL.
Duration of effect: Ocular implant: BRVO/CRVO:
~1 to 3 months (following onset of improvement).

Hypersensitivity to dexamethasone or any component of the formulation or product.

C(UTD)

recommended caution be used if administered to a nursing woman.(UTD)

>10%:
Cardiovascular: Hypertension (13%)
Ophthalmic: Cataract (5% to 68%; incidence increases in patients requiring a second injection), increased intraocular pressure (25%; ?10 mm Hg: 28%; ?30 mm Hg: 15%), conjunctival hemorrhage (22% to 23%).

Diabetic macular edema (pseudophakic or phakic patients scheduled for cataract surgery) or macular edema (following BRVO or CRVO):
Ocular implant: Intravitreal injection: 0.7 mg implant injected in affected eye
Noninfective uveitis:
Ocular implant: Intravitreal injection: 0.7 mg implant injected in affected eye.(UTD)